Lilly launches Tanstrive (Selpercatinib), a RET inhibitor to treat advanced cancers with RET gene… EP News Bureau Jun 25, 2026 Available in India in 40 mg, 80 mg, 120 mg and 160 mg tablet strengths; administered orally twice daily
US FDA approves Retevmo for lung, thyroid cancers with certain genetic mutations EP News Bureau May 9, 2020 It is the first therapy approved specifically for cancer patients with the RET gene alterations
